Pras Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.56 M
- Revenue Growth -88.77%
- Profit Growth -29.88%
- Ebitda -0.03%
- Net Worth -21.96%
- Total Assets -21.20%
About Pras Pharma
Pras Pharma Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 December 2013 and has a history of 11 years and two months. Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹2.56 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Abhijit Patil and Ashalata Kharade serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U52399PN2013PTC149683
- Company No.
149683
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Dec 2013
- Date of AGM
25 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Pras Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashalata Kharade  | Director | 10-Jun-2020 | Current |
| Abhijit Patil | Director | 29-May-2020 | Current |
Financial Performance of Pras Pharma.
Pras Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 88.77% decrease. The company also saw a substantial fall in profitability, with a 29.88% decrease in profit. The company's net worth observed a substantial decline by a decrease of 21.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pras Pharma?
In 2020, Pras Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹2.56 M
Charges Breakdown by Lending Institutions
- Others : 0.14 Cr
- Hdfc Bank Limited : 0.12 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Mar 2018 | Others | ₹1.40 M | Satisfied |
| 21 Aug 2015 | Hdfc Bank Limited | ₹0.46 M | Satisfied |
| 30 Jan 2015 | Hdfc Bank Limited | ₹0.70 M | Satisfied |
How Many Employees Work at Pras Pharma?
Pras Pharma has a workforce of 2 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pras Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pras Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
